HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmartCells Inc.

Division of Merck & Co. Inc.
www.smartinsulin.com

Latest From SmartCells Inc.

Novo Nordisk Makes Long-Term Bet On GBM Technology With Ziylo Buy

Novo Nordisk has bought UK-based start-up Ziylo in hopes of accelerating development of glucose-responsive insulins, but admits any such products are at least ten years away.

Deals Commercial

Sensulin LLC

Sensulin LLC aims to treat diabetes by linking a liposome-encapsulated form of recombinant human insulin with a boronic-acid derivative that is a competitive binder with glucose. If the drug works as envisioned, it would reduce the risk of hypoglycemia that can occur when glucose levels fluctuate during the day, and would also obviate the need for multiple injections and constant monitoring.

BioPharmaceutical

Thermalin Diabetes LLC

Thermalin Diabetes LLC is developing candidates aimed at three separate segments of the insulin analog market, the first, a rapid-acting, ultra-concentrated insulin will complete preclinical proof-of-concept studies this spring. A second, ultra-rapid-acting insulin analog is designed to make mealtime dosing more effective. Finally, Thermalin has figured out a way to make both basal and rapid-acting insulins that are stable in the heat, potentially enabling important new ways to get insulin to patients.

BioPharmaceutical

Biotech Angels Are Going Where VCs Fear To Tread

Many VCs have lost interest in early-stage investing, but angels - individuals who invest their own money alone or in groups - are stepping up to fill the gap. Angels are an especially good fit for for biotech start-ups that don't want to cede control of their companies to VCs too early, if at all. In addition to bringing valuable cash, angels put less pressure on start-ups to achieve an exit within a given time frame than traditional venture investors, and are more willing to accept buyers that may not be the highest bidders but will nevertheless be good stewards for their assets. For their part, companies looking to angels must understand the goals of their potential backers, since these financiers are often motivated by philanthropy and personal interest in a disease.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Todd C Zion, PhD, Pres. & CEO
    Alan Watson, PhD, VP, Bus. Dev.
    Thomas M Lancaster, PhD, VP, R&D
  • Contact Info
  • SmartCells Inc.
    Phone: (978) 927-4246
    100 Cummings Ctr., Ste. 419E
    Beverly, MA 01915
    USA
UsernamePublicRestriction

Register